BPC-157 + TB-500 Stack Guide: The Recovery Combination, Honestly Reviewed

The BPC-157 + TB-500 stack is the single most-asked-about combination in our Cape Town Q&As. The rationale is mechanistic — the two peptides act on partially distinct healing pathways — so the theoretical case for additive effect is reasonable. The empirical case is less complete than the internet would have you believe.

Mechanisms (briefly)

BPC-157 is a 15-amino-acid fragment originally isolated from human gastric juice. In animal models it promotes tendon, ligament, gut and vascular healing, with strong evidence for VEGFR2-mediated angiogenesis.¹ TB-500 is a synthetic analogue of the active region of thymosin β4, an actin-binding peptide that promotes cell migration and tissue repair, with documented effects on cardiac, muscular and dermal wound healing in animal models.²

The mechanistic distinction matters: BPC-157's primary contribution is angiogenic (new blood vessels into the injury site); TB-500's is migratory (cells moving in to do the repair). Theoretically complementary.

What the human evidence actually supports

Honestly? Limited. Both peptides have extensive rodent data and a substantial body of self-reported human experience. Neither has the large randomised human trials you'd want before making strong clinical claims.³ The Cape Town Peptide Club's working position is: the stack appears to help with musculoskeletal injuries and post-surgical recovery in practice, but the published RCT evidence is thin and you should track outcomes carefully.

Common dosing protocol

Self-reported protocols converge on roughly:

• BPC-157: 250–500 mcg SC once or twice daily
• TB-500: 2–5 mg SC once or twice weekly (loading), then 2 mg weekly (maintenance)
• Cycle length: 4–6 weeks for the loading combination, then BPC-157 alone for 4 more weeks
• Washout: 4 weeks fully off before considering another cycle

Timing and administration

• BPC-157 — daily, ideally same time each day; many users report best results dosing AM and PM
• TB-500 — typically once or twice weekly during loading; less critical to time precisely
• Inject SC into rotated sites; for localised injuries, BPC-157 is sometimes injected near (not into) the affected tendon
• Both peptides are stable in solution refrigerated for 2–4 weeks after reconstitution

What to track

• Daily pain/function VAS for the target tissue (1–10)
• Range of motion or strength benchmark at week 0, 2, 4, 6
• hs-CRP and full blood count at baseline and end of cycle
• Subjective sleep, recovery and GI score 1–10 daily

Side-effect profile

Both peptides have a benign acute side-effect profile in self-reports. The honest unknown is long-term safety — TB-500's pro-angiogenic and pro-migratory mechanism is precisely the reason it appears on the WADA prohibited list, and there's a theoretical concern about effects on undiagnosed neoplasia.⁴ For people with a family or personal history of cancer, this stack is not the place to start.

Realistic expectations

If you have a defined musculoskeletal injury — chronic tendinopathy, post-surgical, persistent joint inflammation — most users running this stack with proper rehabilitation report meaningful improvement by week 3–4. If you're running it 'for general recovery' without a defined target tissue, the signal is much harder to see, and you should ask whether a non-peptide protocol (training, sleep, nutrition) is what you actually need.